Tenax Therapeutics, INC. (TENX) — 8-K Filings

All 8-K filings from Tenax Therapeutics, INC.. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

Tenax Therapeutics Files 8-K Report — Dec 17, 2025 Risk: low
On December 17, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
8-K Filing — Nov 12, 2025
Tenax Therapeutics Files 8-K — Sep 16, 2025 Risk: low
On September 16, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with
Tenax Therapeutics Files 8-K for Material Agreement — Sep 9, 2025 Risk: medium
On September 3, 2025, Tenax Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Oxygen Biotherapeutics, Inc., filed
Tenax Therapeutics Files 8-K on Financials — Aug 13, 2025 Risk: low
On August 13, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Tenax Therapeutics Files 8-K with Corporate Updates — Jun 17, 2025 Risk: low
On June 11, 2025, Tenax Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote
Tenax Therapeutics Files 8-K: Material Agreement, Equity Sales — Mar 6, 2025 Risk: medium
On March 4, 2025, Tenax Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
Tenax Therapeutics Announces Director and Officer Changes — Dec 4, 2024 Risk: medium
On December 2, 2024, Tenax Therapeutics, Inc. filed an 8-K report detailing the election of new directors and the appointment of new officers. The filing also i
Tenax Therapeutics Announces Director Changes and Stockholder Meeting — Oct 30, 2024 Risk: medium
On October 25, 2024, Tenax Therapeutics, Inc. filed an 8-K report detailing the departure of Director Dr. David J. Mazzo and the election of new Director Dr. Da
Tenax Therapeutics Files 8-K Report — Aug 12, 2024 Risk: low
On August 12, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Tenax Therapeutics Files 8-K for Financial Statements — Aug 6, 2024 Risk: low
On August 6, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material even
Tenax Therapeutics Appoints New Officers, Elects Directors — Jun 13, 2024 Risk: medium
On June 7, 2024, Tenax Therapeutics, Inc. announced the appointment of Dr. Christopher P. Bartus as Chief Medical Officer and Dr. Jonathan P. Stine as Chief Sci
Tenax Therapeutics Files 8-K on Financials — Mar 28, 2024 Risk: low
On March 28, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with
Tenax Therapeutics Files 8-K on Feb 22nd Event — Feb 23, 2024 Risk: medium
Tenax Therapeutics, Inc. (TENAX) filed an 8-K on February 23, 2024, reporting an event that occurred on February 22, 2024. The filing indicates a current report
Tenax Therapeutics Enters Material Definitive Agreement — Feb 20, 2024 Risk: medium
Tenax Therapeutics, Inc. entered into a Material Definitive Agreement on February 19, 2024. This 8-K filing, dated February 20, 2024, reports on this agreement,
TENAX THERAPEUTICS FILES 8-K ON MATERIAL AGREEMENT; DETAILS UNDISCLOSED — Feb 12, 2024 Risk: medium
On February 8, 2024, Tenax Therapeutics, Inc. (TENX) filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing
TENAX THERAPEUTICS FILES 8-K: ROUTINE 'OTHER EVENTS' DISCLOSURE — Feb 8, 2024 Risk: low
Tenax Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an event that occurred on February 7, 2024. This filing is a routine update to the SEC, ind
Tenax Therapeutics Files 8-K on Feb 6, Confirms Nasdaq Listing — Feb 6, 2024
Tenax Therapeutics, Inc. filed an 8-K on February 6, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates tha
Tenax Therapeutics Confirms Nasdaq Listing for Common Stock — Jan 19, 2024
Tenax Therapeutics, Inc. filed an 8-K on January 18, 2024, to update its registration information, specifically confirming its Common Stock, $0.0001 par value p
TENAX THERAPEUTICS FACES NASDAQ DELISTING THREAT — Jan 12, 2024
Tenax Therapeutics, Inc. announced on January 9, 2024, that it received a notice from the Nasdaq Stock Market indicating its failure to meet continued listing s
TENAX THERAPEUTICS Reports Shareholder Rights, Bylaw Changes — Jan 5, 2024
TENAX THERAPEUTICS, INC. filed an 8-K on January 5, 2024, reporting an event on December 29, 2023, concerning "Material Modifications to Rights of Security Hold

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX